Replies to post #137851 on Cytodyn Inc (CYDY)

[daemon57]

There's a company an israel that uses nanoparticles to cross the BBB with a new delivery system (amongst others).

https://www.sciencedirect.com/science/article/abs/pii/S0168365917310829

If sometime in the future, CYDY can partner with them and use that delivery mechanism, world's our oyster (IMHO).

GLTU/A.

[Borel Fields]

Thanks - obviously I'm a beginner on this subject and not medically trained.

In the stroke PR, Kelly is clear about the "macaque model" re leronlimab crossing BBB, citing 70%-75% receptor occupancy in the brain. Is that a trauma situation?

I was musing leronlimab could travel there on the CCR5 receptor of a T-cell, so would only cross in the adverse situations that would let the T-cell cross.

I apologize if the above is nonsense.

[misiu143]

CTMedic , we know now for sure , base on studies on primates , by Dr Scott Kelly statements , that Leronlimab is crossing BBB ,
I believe at some stage , they find 75% density occupied by Leronlimab...

So regardless if COVID-19 virus crossing the BBB ,
( and I read that it does) , or just immunological abnormalities , we should be correcting these.

It is similar like in HIV patients , we see
" HIV dementia " not being corrected by HAART drug , but we expect that it is by Leronlimab....

All this is giant , not talk by many , since of course BP dont want to talk about it..

But after we approve , and after learning the same things happening in COVID ,
one of this day it should be , it will be..
" talk of the town "

all IMO.